These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15528874)

  • 1. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.
    Nakao N; Seno H; Kasuga H; Toriyama T; Kawahara H; Fukagawa M
    Am J Nephrol; 2004; 24(5):543-548. PubMed ID: 15528874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
    Nakao N; Yoshimura A; Morita H; Takada M; Kayano T; Ideura T
    Lancet; 2003 Jan; 361(9352):117-24. PubMed ID: 12531578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
    Ichihara A; Hayashi M; Kaneshiro Y; Takemitsu T; Homma K; Kanno Y; Yoshizawa M; Furukawa T; Takenaka T; Saruta T
    Am J Kidney Dis; 2005 May; 45(5):866-74. PubMed ID: 15861352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
    Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
    J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto K
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):525-32. PubMed ID: 19640361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels.
    Schmieder RE; Schmidt ST; Riemer T; Dechend R; Hagedorn I; Senges J; Messerli FH; Zeymer U
    Hypertension; 2014 Nov; 64(5):1067-72. PubMed ID: 25259741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.
    Svensson P; de Faire U; Sleight P; Yusuf S; Ostergren J
    Hypertension; 2001 Dec; 38(6):E28-32. PubMed ID: 11751742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study.
    Klein R; Moss SE; Sinaiko AR; Zinman B; Gardiner R; Suissa S; Donnelly SM; Kramer MS; Goodyer P; Strand T; Mauer M
    Ophthalmology; 2006 Dec; 113(12):2231-6. PubMed ID: 16996597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
    Verdecchia P; Schillaci G; Reboldi GP; Sacchi N; Bruni B; Benemio G; Porcellati C
    Blood Press Monit; 2000 Jun; 5(3):187-93. PubMed ID: 10915233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.
    Berl T
    J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):1-8. PubMed ID: 19286752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.